Fresh Tracks Therapeutics, Inc. (FRTX)
(Delayed Data from OTC)
$0.74 USD
0.00 (0.00%)
Updated Sep 11, 2024 02:51 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Fresh Tracks Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 8 | 7 | 0 | 2 | 8 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 8 | 7 | 0 | 2 | 8 |
Selling & Adminstrative & Depr. & Amort Expenses | 14 | 28 | 41 | 23 | 32 |
Income After Depreciation & Amortization | -6 | -22 | -40 | -21 | -24 |
Non-Operating Income | 1 | 0 | 1 | 0 | 3 |
Interest Expense | 0 | 0 | 0 | 0 | 2 |
Pretax Income | -6 | -21 | -39 | -21 | -24 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -6 | -21 | -39 | -21 | -24 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -6 | -21 | -39 | -21 | -24 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -6 | -22 | -40 | -21 | -23 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 2 |
Income After Depreciation & Amortization | -6 | -22 | -40 | -21 | -24 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 5.40 | 2.81 | 1.78 | 0.54 | 0.07 |
Diluted EPS Before Non-Recurring Items | -1.06 | -7.51 | -22.07 | -38.29 | -230.18 |
Diluted Net EPS (GAAP) | -1.06 | -7.51 | -22.07 | -38.29 | -202.70 |
Fiscal Year end for Fresh Tracks Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | 0.00 | 7.94 | 0.05 |
Cost Of Goods | NA | NA | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | NA | 0.00 | 7.94 | 0.05 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 1.65 | 5.95 | 2.42 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | -1.65 | 1.99 | -2.37 |
Non-Operating Income | NA | NA | 0.41 | 0.11 | 0.08 |
Interest Expense | NA | NA | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | NA | -1.24 | 2.10 | -2.28 |
Income Taxes | NA | NA | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | NA | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | NA | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | NA | -1.24 | 2.10 | -2.28 |
Extras & Discontinued Operations | NA | NA | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | NA | -1.24 | 2.10 | -2.28 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 5.40 | 5.91 | 5.91 |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.20 | 0.32 | -0.39 |
Diluted Net EPS (GAAP) | NA | NA | 0.15 | 0.32 | -0.39 |